Search

Now showing items 1-2 of 2

Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.

Rajan, P; Sooriakumaran, P; Nyberg, T; Akre, O; Carlsson, S; Egevad, L; Steineck, G; Wiklund, NP (2017-11-01)

Purpose To determine the effect of comorbidity on prostate cancer (PCa)-specific mortality across treatment types. Patients and Methods These are the results of a population-based observational study in Sweden from 1998 ...

Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.

Sweeney, CJ; Petry, R; Xu, C; Childress, M; He, J; Fabrizio, D; Gjoerup, O; Morley, S; Catlett, T; Assaf, ZJ;... (American Association for Cancer Research, 2024-09-13)

PURPOSE: Enzalutamide after abiraterone progression is commonly used in metastatic castration-resistant prostate cancer despite a low rate of clinical benefit. Analyzing IMbassador250, a phase III trial assessing enzalutamide ...